Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Biohaven Ltd.NYSE: BHVN

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity falls 90.9% from a year ago

Total equity stood at $12.22M at the end of Q2 FY2026, down 90.9% from a year earlier and down 90.6% from the prior quarter. Over 3 fiscal years it compounded at -54.1% a year.

Context

  • Total equity amounted to 3.3% of total assets at the end of Q2 FY2026, down 21.2 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -90.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$12.22M-90.6% QoQ
Last fiscal yearDec 2025
$52.07M-87.7% YoY
Year agoJun 2025
$134.59M-90.9% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-90.9%——
1 year-87.7%——
3-year CAGR-54.1%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
52.07M USD
Year-over-year change
-87.7%
4-year CAGR
-13.9%

Total Equity vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -90.9% is the lowest of 11, against a peer median of +6.3%.
  • Total equity amounts to 3.3% of total assets for BHVN, versus a peer median of 79.2%.
BHVN Competitors
Total Equity for BHVN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABCLAbCellera Biologics Inc.Sep 2026$1.06B USD+10.2%-7.8%70.8%
CLDXCelldex Therapeutics, Inc.Sep 2026$649.47M USD+8.5%+17.4%90.0%
NTLAIntellia Therapeutics, Inc.Mar 2026$620.94M USD-20.4%-18.4%81.8%
IMNMImmunome, Inc.Sep 2026$454.3M USD+72.1%+236.5%89.9%
VERAVera Therapeutics, Inc.Jun 2026$407.76M USD-12.9%+98.8%76.5%
IMCRImmunocore Holdings plcMar 2026$393.67M USD+4.0%+4.0%36.7%
ZBIOZenas BioPharma, Inc.Mar 2026$335.83M USD+18.1%—44.9%
SIONSionna Therapeutics, Inc.Mar 2026$288.21M USD-18.1%—94.5%
PHVSPharvaris N.V.Sep 2026€264.97M EUR-15.1%+22.0%89.8%
XERSXeris Biopharma Holdings, Inc.Mar 2026$13.01M USD+137.0%-32.8%3.3%
BHVNBiohaven Ltd.Jun 2026$12.22M USD-90.9%-54.1%3.3%
Peer median (excluding BHVN) —+6.3%+10.7%79.2%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents76.06M204.88M248.4M99.13M229.96M
Short-term Investments0260.46M133.42M386.86M89.18M
Net Receivables046.14M13.25M2.6M0
Inventory00000
Other Current Assets12.03M54.54M12.13M508K2.17M
Total Current Assets94.82M586.97M442.45M538.47M368.33M
Property, Plant & Equipment (Net)17.68M52.44M48.58M53.71M15.96M
Goodwill1.39M1.39M1.39M1.39M1.39M
Intangible Assets18.95M18.4M18.4M18.4M18.4M
Long-term Investments6M0000
Tax Assets00000
Other Non-current Assets3.22M2.59M2.4M3.13M47.36M
Total Non-current Assets47.24M74.82M70.77M76.64M83.12M
Total Assets142.06M661.78M513.21M615.11M451.45M
Account Payables4.78M10.7M15.58M18.03M11.64M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities9.54M14.6M35.7M84.71M59.49M
Total Current Liabilities41.94M90.02M55.42M154.23M115.93M
Long-term Debt0000238.9M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.64M2.41M2.25M4.66M4.58M
Total Non-current Liabilities5.44M32.99M29.81M37.45M283.44M
Total Liabilities47.37M123.01M85.24M191.67M399.38M
Common Stock34.69M615.74M887.53M1.66B1.93B
Retained Earnings0(91.12M)(499.29M)(1.35B)(2.08B)
Accumulated OCI0284K(65K)79K8.35M
Other Stockholders Equity00000
Minority Interest60M0000
Total Equity94.69M538.77M427.98M423.44M52.07M
Total Debt3.24M33.6M30.88M36.58M284.61M
Net Debt(72.82M)(171.28M)(217.53M)(62.55M)54.66M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.